Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Platinum-Treated Advanced Urothelial Bladder Cancer (IMvigor210 Cohort 2)
NCT02108652Phase 2Completed
- Sponsor
- Roche
- Start
- May 2014
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of atezolizumab in Urothelial Bladder Cancer (UBC), sponsored by Roche. Started May 2014; status: completed.
02
Drugs
atezolizumab
03
Conditions
Urothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT02108652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108652.